Hemolytic disease and other neonatal jaundice

Trials started per year, stacked by phase (darker = later phase). Source: ClinicalTrials.gov via Clin2, which tracks studies recruiting in recent years — early years undercount.

Hemolytic disease and other neonatal jaundice are curable or preventable in most cases. Anti-D immunoglobulin prevents Rh disease in at-risk pregnancies, while phototherapy and exchange transfusion effectively treat severe hyperbilirubinemia, preventing kernicterus. Deaths have been falling about 2% a year, reflecting improved screening and care. The single most important milestone is the development of anti-D immunoglobulin, which dramatically reduced Rh disease. However, access gaps remain in low-resource settings, so not all infants benefit equally from these proven interventions.

What causes hemolytic disease of the newborn?

It occurs when maternal antibodies attack fetal red blood cells, often due to Rh or ABO blood group incompatibility, leading to anemia and severe jaundice.

How is hemolytic disease prevented?

Anti-D immunoglobulin is given to Rh-negative mothers during pregnancy and after birth to prevent sensitization, reducing the risk of Rh disease in subsequent pregnancies.

What is the current trend in deaths from this condition?

Deaths have been falling about 2% per year, thanks to better prenatal screening, preventive anti-D use, and effective treatment of jaundice.

What is the most important medical advance for this disease?

The development of anti-D immunoglobulin is the landmark milestone, as it prevents Rh disease and has saved countless lives since its introduction.

Are there ongoing clinical trials for new treatments?

Yes, 23 trials have started in the last 5 years, including 1 phase-3 trial, and 28 are currently active, exploring improved prevention and treatment options.